Some meta-analyses and pharmacovigilance data suggest a slightly higher myocarditis risk with PD-1 inhibitors (e.g., pembrolizumab, nivolumab) than with PD-L1 inhibitors (e.g., durvalumab, atezolizumab). This evidence concerns the gene CD274 and myocarditis.